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Background: Dispensed prescription medicine labels (prescription labels) are impor-
tant information sources supporting safe and appropriate medicines use.
Objective: To develop and user test patient- centred prescription label formats.
Methods: Five stages: developing 12 labels for four fictitious medicines of varying 
dosage forms; diagnostic user testing of labels (Round 1) with 40 consumers (each 
testing three labels); iterative label revision, and development of Round 2 labels 
(n = 7); user testing of labels (Round 2) with 20 consumers (each testing four labels); 
labelling recommendations. Evaluated labels stated the active ingredient and brand 
name, using various design features (eg upper case and bold). Dosing was expressed 
differently across labels: frequency of doses/day, approximate times of day (eg morn-
ing), explicit times (eg 7 to 9 AM), and/or explicit dosing interval. Participants’ abil-
ity to find and understand medicines information and plan a dosing schedule were 
assessed.
Results: Participants demonstrated satisfactory ability to find and understand the 
dosage for all label formats. Excluding active ingredient and dosing schedule, 14/19 
labels (8/12 in Round 1; 6/7 in Round 2) met industry standard on performance. 
Participants’ ability to correctly identify the active ingredient varied, with clear medi-
cine name sign- posting enabling all participants evaluating these labels to find and 
understand the active ingredient. When planning a dosing schedule, doses were 
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1  | INTRODUC TION
Labels are fundamental sources of written information for pre-
scription medicines, particularly for the directions for use.1 OTC 
medicine labels display fixed and standardized directions for use. 
However, the content of dispensed prescription medicine labels 
(henceforth referred to as prescription labels) varies according to 
prescriber instructions, which can impact safe and appropriate 
use of medicines.2,3 Pharmacists are responsible for interpreting 
and transcribing this information onto labels in a way to ensure 
understanding by medicine users. Although written instructions 
are sometimes supported by verbal counselling,4 counselling is 
not always provided when prescription medicines are supplied,4,5 
and medicine users rely on the label as the source of information. 
Written instructions can be misinterpreted by people,6- 9 where 
pharmacists believe reading and/or understanding prescription 
labels to be challenging for patients.10
Health literacy has an impact on people's understanding of pre-
scription labels. Functional health literacy is important in people's 
ability to find, understand and act on such information.11 Suboptimal 
health literacy is a global issue,12 including in Australia.13 Label for-
mat, content and design must synergistically support people's ability 
to find and understand information.
Previous reviews have highlighted the evidence for informa-
tion content and design practices which include strategies such as 
people- centred structuring of labels, use of known good information 
design strategies (eg appropriate white space, optimal font size), use 
of plain language and explicit directions for use.14- 16 People want 
specificity in the directions for use stated on labels,17,18 effective 
amounts of white space,19 larger font size,17,19 all horizontal text on 
labels19 and appropriate use of bolding to emphasize key information 
such as directions for use.17
Actual labels and implementation of evidence- based label-
ling strategies in practice can vary.2,20- 22 Legislation pertaining to 
prescription labels tends to be content- centric, whereas design is 
influenced by pragmatic factors such as dispensing software(s), label 
printing systems and space available on packaging for dispensed 
labels.
Recommendations from an Australian national round table23 in-
cluded the development and implementation of a standardized label 
format.23 Standardization of dispensed labels has been proposed as 
a means to provide understandable dosage information, such as via 
the Universal Medication Schedule (UMS).24,25 While prescription 
labelling standards have been developed internationally,26,27 there 
are currently no nationally implemented guidelines in Australia for 
developing user- friendly prescription labels that can be understood 
by patients with low health literacy. This study aimed to develop and 
user test prescription labels, focusing primarily on instructions for 
use and active ingredient information presentation, to inform a na-
tional dispensed prescription medicine label standard.
2  | METHODS
‘User testing’ is a diagnostic process using individual interviews with 
small numbers of lay people.28,29 It determines whether the key 
information in the document is easy to find and understand. After 
testing, good practice in information writing and design is applied to 
address shortcomings identified, and testing is repeated iteratively. 
User testing is widely used in Europe to determine the readability of 
patient leaflets,28,30 and European legislation has led to manufac-
turers undertaking user testing on all patient information leaflets as 
part of the licence application. As a form of diagnostic testing, only 
small numbers of people (generally cohorts of 10) are needed to di-
agnose problems.
This study comprised two rounds of label development and 
consumer user testing.31 In Round 1, 12 labels (Figure S1A in the 
Supplement) for four fictitious medicines of varying dosage forms were 
developed using principles of good information writing and design.32,33 
The four fictitious medicines (brand name and active ingredient) were 
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correctly spaced if the label stated a dosing interval, or frequency of doses/day. Two- 
thirds planned appropriate dosing schedules using a dosing table.
Conclusions: Effective prescription label formatting and sign- posting of active ingre-
dient improved communication of information on labels, potentially supporting safe 
medicines use.
Patient and Public Involvement: Consumers actively contributed to the development 
of dispensed prescription medicine labels. Feedback from consumers following the 
first round was incorporated in revisions of the labels for the next round. Patient and 
public involvement in this study was critical to the development of readable and un-
derstandable dispensed prescription medicine labels.
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(a) Lubidrops (active ingredient: hypromethylmellose) 1% eye drops; (b) 
Mixicillin (active ingredient: pentoampicillin) 500 mg/5 mL suspension; 
(c) Vipparoll (active ingredient: myclofenac) 75 mg capsules or tablets, 
or 75 mg/5 mL suspension; and (d) Tapisoy (active ingredient: ocylo-
hydrosteroid) 0.05% cream. Labels were developed with variations 
in design, formatting, content and dosage form- specific information 
(Table 1). Based on Round 1 user testing findings, six labels were de-
veloped for Round 2 (Table 2); an additional label based on the UMS 
label format24,25 was also developed and tested (Figure 1; Figure S1B 
in the Supplement).
2.1 | Participant user testing
User testing was employed to evaluate the usability of the study la-
bels by determining people's ability to find the relevant information 
and understand the information found. All interviews were conducted 
face- to- face at The University of Sydney, in rooms commonly used for 
meetings or interviews, and participants were reimbursed AUD$40.
Cohorts of 10 demographically similar consumers user tested 
each label in accordance with user testing protocol.28 Labels were 
clustered into groups of three (Round 1) and four (Round 2) for 
evaluation to ensure diverse label variations within each cluster 
and enable maximum label variation (content, design and wording) 
assessment. The broad factors that underpinned label clustering 
included the label size (with at least one small and one large- sized 
label included in each cluster), ‘standard’ information content (such 
as single column and two column label formats), active ingredient 
and brand name (presented using varying formatting combinations 
reflecting use of upper case, sentence case, lower case, italics), and 
formatting and wording differences for instructions/directions for 
use. For specific details, please refer to Tables 1 and 2.
Recruitment was conducted through online advertisements, re-
cruitment flyer distribution and passive snowballing, according to set 
inclusion/exclusion criteria.30,34,35 Participants were eligible if they 
were aged 18 years or older, and comfortable reading and speaking 
English without needing a translator.
Participants were excluded if they were a healthcare professional 
or employed in an occupation which dealt with medicines informa-
tion, had self- reported visual impairment, had significant cognitive 
impairment affecting participation or had participated in user testing 
in the previous six months.
Participants were allocated to each cluster of labels to ensure an 
equal distribution of participant demographics (age, sex and educa-
tion) across the cohorts.
Each participant in Round 1 (total n = 40; December 2017 to 
January 2018) evaluated three unique labels for different dosage 
forms in the following order: a tablet or capsule, suspension, and 
eye drops or cream. Round 2 participants (total n = 20; April 2018) 
each user tested four labels (three unique labels per cohort, and 
one common tablet label to evaluate ‘as required’ (prn) directions 
for use, including maximum dose information). For Round 2, the first 
three unique labels for different dosage forms in each cluster were 
evaluated in one of two orders: a cream, suspension and capsule; or 
a capsule, suspension and eye drops. The common tablet label was 
then evaluated as the last label in both Round 2 clusters. Round 2 
participants were naïve to the user testing process in Round 1.
User testing consisted of three steps. Each participant read the 
first label and responded to the structured core user testing ques-
tionnaire (UTQ) and dose application question(s) asked, as relevant 
to the label. The process was then repeated for subsequent labels. 
Finally, semi- structured questions were asked, and the participant 
completed the demographic survey and questions on self- perceived 
health literacy (administered in previous user testing studies,30,35,36 
adapted from validated questions37).
2.2 | User testing questionnaire
A study- specific UTQ, including dose application questions, was de-
veloped (based on previous research34- 36) and used to evaluate the 
key information points per label (Table 3). Questions were adapted 
to the content of each label; and all questions were asked in a fixed 
order for each label cluster. The core UTQ items on the ‘standard’ 
information included (patient name, expiry date) were only asked 
in relation to the first label evaluated by each participant. A show 
card was provided to the participant for the question on planning 
a daily dosing schedule for three hypothetical medicines they were 
currently taking, plus the new medicine corresponding to the label 
that was being tested.
2.3 | Data analysis
All interviews except one were audio recorded. One participant did not 
wish to be recorded, and their responses were written down by the re-
searcher. Responses to each UTQ item for each label were transcribed 
verbatim, combined with the one participant's written responses, and 
independently coded by two different researchers against the model 
answer for the primary outcome measures: ability to find the relevant 
information and ability to understand the information that was found. 
Labels were regarded as performing well if they met the user test-
ing industry standards criteria,38 that is, a minimum of nine out of 
10 participants were able to find the information, and of these, nine 
participants were able to demonstrate complete understanding of the 
information. Therefore, more than eight out of 10 participants were 
expected to be able to find and understand the key information.
Dose application questions relating to the pain scenario and 
cream label were analysed using a process adapted from a previous 
study.36 This involved inductive analysis of the responses, and the 
subsequent development and refinement of a coding framework 
(Table S1 in the Supplement).
Responses to the semi- structured interview questions were 
transcribed verbatim and thematically analysed39 with the help of 
matrix displays.40 The analysis centred on identifying findings that 
supported or challenged the user testing results.
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3  | RESULTS
Participant demographics have been presented in Table S2 (in the 
Supplement). The vast majority of participants self- reported to 
be extremely or quite confident in completing medical forms by 
themselves.
3.1 | User testing findings
Excluding the responses to active ingredient and dosing schedule sce-
narios, 14 of the 19 labels met the industry standard on performance 
for the core UTQ items: 8/12 of the Round 1 labels, and 6/7 of the 
Round 2 labels (Table S3 in the Supplement). Overall label perfor-
mance improved between Round 1 and 2. At least 9/10 participants 
were able to both find and understand the patient name and expiry 
date of the medicine from each label, indicating that the label formats 
used were effective in conveying this information (Table 4).
Across the label formats, except for the medicine strength for 
Label 18 (eye drops, 1%), medicine strength and dosage were gener-
ally well found and understood (Table 4); at least 8/10 participants 
found and understood the relevant information per label. Across all 
label formats, participants demonstrated satisfactory ability to find 
and understand the dosage on the labels. No marked difference in 
dosage understanding was seen between the use of words or num-
bers to convey numerical dosage information on the labels.
TA B L E  2   Variations in labels evaluated in Round 2 of user testing
Label aspect Label 13a  Label 14A Label 14Bb  Label 15 Label 16 Label 17 Label 18
Label sizec  Small Large Large Large Large Small Small
Single column or two 
column
Single column Single column Single column Single column Two column Two column Two column








Lower case Sentence case
Brand name Sentence case 
Bold




Sentence case Sentence case
Active ingredient 
presented first then 
brand name
N Y Y N Y N Y
Dose form Tablets Capsules Capsules Suspension Suspension Cream Eye drops
Instruction (I): #d of 
tabs/caps/mL/other
# Words # # # Fingertip (FT) Words
(I): Bold Y (#, interval, 
max. daily 
dose)
Y (#, frequency, 
approx. times 
of day in 
table)
Y (#, approx. 
times of day 
in table)
Y (#, frequency, 
'with food')
Y (#, approx. 
times of day)
Y (FT, 'affected 
skin', 
frequency)
Y (#, 'left eye', 
'night')




(I): Sentence Y Y Y Y Y Y Y
(I): Table N Y Y N N N N
(I): Prn Y N N N N N N
(I): Food N N N Y (with food) Y (empty 
stomach)
N N
(I): Hours Y (interval) Y (interval) N N (time interval 
in brackets)
N N N
(I): Time of day N Y (approx. 
times of day)
Y (approx. 
times of day, 
with specific 
time range)
N Y (approx. 
times of day)
N Y (approx. time 
of day)
Note: The clusters and corresponding labels for Round 2 were: Cluster 5: Labels 17, 16, 14A and 13; Cluster 6: Labels 14B, 15, 18 and 13.
Abbreviations: N, No; Y, Yes; FT, Fingertip.
aEvery participant reviewed Label 13 as the last label to be user tested in each cluster for Round 2— only the dosage- related questions were asked. 
bLabel 14B was the 7th label requested by Canberra Hospital for inclusion in Round 2 of the user testing. 
cLarge label dimensions (except for Label 14B) = 102 mm × 52 mm; Label 14B dimensions = 102 mm × 58 mm; Small label 
dimensions = 80 mm × 40 mm. 
d#refers to number of tablets or capsules or millilitres of suspension or drops included on the label; for example, 2 or 5 mL, respectively. 
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Labels for non- solid dosage forms demonstrated issues with par-
ticipant understanding of the medicine's strength. Qualitative find-
ings indicated that the medicine strength for the suspension was not 
clearly communicated when expressed in the format ‘500 mg/5 mL’. 
A statement explaining the medicine strength (‘Each 5 mL of the 
syrup contains 500 mg pentoampicillin’), included on Label 15 
(Round 2), was well received overall.
The strength of the cream proved problematic for 2/10 partici-
pants evaluating Label 5 (Round 1); their responses indicated confu-
sion between the weight of the cream and medicine strength (ie 25 g 
or 50 g instead of 0.5%).
A marked difference in the eye drops labels between Rounds 
1 and 2 for the medicine strength was noted. In Round 1, of those 
who found the information, 2/18 participants did not under-
stand the information about the strength of the eye drops; that 
is, what 1% meant. In Round 2, 4/10 participants could not find 
the strength of the eye drops, confusing volume (ie 10 mL) for the 
strength.
3.2 | Active ingredient identification
Participants’ ability to correctly identify the active ingredient 
varied between labels, influenced by its formatting and position-
ing (Table S4 in the Supplement). Only Labels 15 and 16 (Round 
2), which had the active ingredient and brand name clearly 
F I G U R E  1   Examples of study labels 
evaluated in Round 2 of consumer 
user testing (see Figure S1A,B in the 
Supplement for the complete list of labels 
evaluated)
Label 14B
(102 mm x 58 mm)
Label 15
(102 mm x 52 mm)
Label 17
(80 mm x 40 mm)
Label 18
(80 mm x 40 mm)
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TA B L E  3   Overview of core user testing questionnaire (UTQ) items and dose application questions
Question type Key point addressed Comments
Core UTQ item (‘standard’ 
information content)
Name of patient Key points used as proxy measure to determine whether differences in the overall 
label format had an impact on usabilityExpiry date
Core UTQ item Active ingredient Asked for all labels except for Label 13 (evaluated by all Round 2 participants)
Strength Asked for all labels except for Label 13 (evaluated by all Round 2 participants)
Dosage Asked for all labels
Maximum dose Relevant to Labels 8, 9, 13 (‘as required’ (prn) medicines) only
Use in relation to food Relevant to Labels 6, 7, 10, 15, 16 (suspension labels) only
Discard- by date Relevant to Labels 11, 12, 18 (eye drops labels) only
Dose application questions Action to be taken in pain 
scenario
Scenario presented once per participant in relation to a tablet / capsule label:
• Hypothetically experiencing back pain at 9 AM
• Asked to specify the medication- taking times in the day if they had constant 
back pain
Planning of dosing schedule 
scenario
Show card presented together with scenario:
• Hypothetically taking three medicines (X, Y, Z), and a new fictitious medicine 
(tablets / capsules)
• Asked to tabulate complete dosing schedule for all four medicines for one day
• Analysed using coding framework determined a priori
Amount of cream to apply Relevant to Labels 5, 17 only
TA B L E  4   Summary of Round 1 and 2 user testing questionnaire (UTQ) findings (quantitative)a
aIn Round 1, each participant evaluated 3 different labels (comprising 1 label cluster) in the following order: 1) A tablet / capsule label; 2) A suspension 
label; and 3) A cream or eye drops label. In Round 2, each participant evaluated 3 different labels in one of the following orders: 1) A cream label 
(Cluster 5) OR capsule label (Cluster 6); 2) A suspension label (both Clusters 5 and 6); and 3) A capsule label (Cluster 5) OR eye drops label (Cluster 6). 
Every participant reviewed Label 13 as the last label to be user tested in each cluster for Round 2— only the dosage- related questions were asked.
bF = Found (number who found the relevant information on the label); U = Understood (number who understood the relevant information found).
cn/a = not applicable or no question asked.
dThis question involved a show card which was provided to the participant. For this question, the participant was required to plan a daily dosing 
schedule for 3 hypothetical medicines they were currently taking, plus the new medicine corresponding to the label that was being tested. As dosage 
was addressed in a previous question, responses were coded using the dosing schedule. Therefore, the number of participants denotes the number 
who were able to plan an appropriate dosing schedule.
eThis refers to discarding 28 days after opening the eye drops.








Round 1 2 1 2 1 2 1 2
Label 
cluster
1 2 3 4 5 and 6 5 6 2 3 1 4 6 5 2 4 5 1 3 6




Label 6 Label 7 Label 9 Label 10 Label 15 Label 16 Label 2 Label 5 Label 17 Label 
11





Fb Ub F U F U F U F U F U F U F U F U F U F U F U F U F U F U F U F U F U F U




10 10 10 10 10 10 9 9 n/ac n/a n/a n/a 10 10 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 10 10 n/a n/a n/a n/a n/a n/a
Acve 
ingredient
7 7 2 2 4 4 3 3 n/a n/a 7 7 1 1 3 3 3 3 7 7 5 5 10 10 10 10 3 3 5 5 8 8 9 9 8 8 9 8
Strength 10 10 10 10 9 9 8 8 n/a n/a 9 9 10 10 10 10 10 10 10 10 10 10 9 9 10 10 10 10 8 8 9 9 9 8 9 8 6 6
Expiry date 10 10 10 9 10 10 10 10 n/a n/a n/a n/a 10 9 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 10 10 n/a n/a n/a n/a n/a n/a















n/a n/a n/a n/a n/a n/a 10 8 20 20 n/a n/a n/a n/a n/a n/a n/a n/a 10 10 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Discard-by 
datee
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 10 9 10 10 10 10
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sign- posted, enabled the entire cohort to find and understand the 
active ingredient. There were five formatting combinations that 
appeared to impact participant identification and discernment be-
tween active ingredient and brand name. Firstly, active ingredi-
ent presented in bold or upper case bolded font contributed to 
poorer ability to correctly identify the active ingredient (Labels 3, 
4, 6, 7, 8 compared to Label 1). Secondly, formatting that was dif-
ferent to current practice had an impact; in particular, where the 
active ingredient was presented in bold first, then the brand name 
in brackets (such as with Label 14B, the worst performing label, 
which was understood and reported by participants as formatting 
that was opposite to current practice). Thirdly, sign- posting of ac-
tive ingredient and brand name helped enable participants to cor-
rectly determine the active ingredient when it was sign- posted. 
Fourthly, active ingredient included in brackets appeared to im-
prove participants’ ability to discern the active ingredient. And fi-
nally, the active ingredient and brand name itself, where a lengthy 
and technical active ingredient name, for example with the eye 
drops, likely supported its identification.
Participants reported co- location of active ingredient and med-
icine strength, using upper case and/or bolding for the brand name, 
and using italics for the active ingredient as factors considered when 
discerning between the active ingredient and brand name.
3.3 | Dosing schedule scenario
The majority of Round 1 participants were able to plan an appro-
priate daily medication schedule for four medicines (X, Y, Z, plus 
study medicine) (Table 4). However, 9/12 participants that nomi-
nated inappropriate schedules demonstrated scheduling issues 
for medicines X, Y or Z (listed on the show card provided for this 
question). The remaining 3/12 participants had issues related to 
the study medicine (Vipparoll tablets/capsules), either missing the 
evening dose or difficulty in observing the correct dosing interval.
Eight of the 20 Round 2 participants planned inappropriate 
schedules. Of these, three demonstrated Vipparoll dosing issues 
where the time between the evening and bedtime doses was less 
than the 6- hour dosing interval (Label 14A).
3.4 | Dose application
3.4.1 | Pain scenario
When participants were asked to explain how they would take the 
medicine (Labels 1, 2, 4, 8, 14A and 14B) for the rest of the day if 
their pain started at 9 AM (Table S5 in the Supplement), Labels 8 
(stating an explicit 6- hour dosing interval) and 14B (simpler direc-
tions for use and tabulated dosing) best enabled appropriate dose 
application. Interestingly, 3/10 omitted a dose for Label 14A (sen-
tence instructions and tabulated dosing). Adhering to the 6- hour 
dosing interval took precedence over the direction to take four 
doses per day for these participants. A further 2/10 participants did 
not consistently observe the 6- hour dosing interval. Doses were ap-
propriately spaced by seven and nine participants if the label stated 
the frequency of doses per day (Label 1) or a specific dosing interval 
(Label 8), respectively. Approximate times led to shortened dosing 
intervals, as seen for Label 3.
3.4.2 | Cream dose application scenario
When asked how much cream they would apply, participants ac-
knowledged that the label (Label 5) did not specify an amount. How 
much cream to be applied was deemed to be dependent on the size 
of the rash, perceived appropriate amount, and/or observed effect 
of the cream with adjustment of the amount if necessary.
In general, understanding of ‘1 fingertip amount’ was either to 
squeeze or dab an amount of cream onto the fingertip and ensure 
that there was enough to cover the area or squeeze a small amount 
onto the fingertip.
4  | DISCUSSION
Good information writing and design principles, the expertise of the 
research team and the application of user testing supported the de-
velopment of dispensed prescription medicine labels that performed 
well. The majority of labels met user testing benchmark standards 
for most of the core UTQ items.
Changes in how ‘standard’ or administrative information (ie 
patient name, prescriber name, expiry date, date of dispensing, 
pharmacy name and address, and reference number content) was 
formatted (eg single column versus two column) had little impact on 
how the patient name and expiry date on the label were found and 
understood. This indicates that either approach is acceptable, and 
emphasis should be placed on separating administrative informa-
tion from medicine- related information, as endorsed by the United 
States prescription labelling standard.26
Medicine- related information communication was influenced 
by formatting. Determining the active ingredient proved problem-
atic and dosage information expression influenced how well partic-
ipants could apply the information to a dosing scenario. Previous 
studies have largely focused on evaluating understanding of the 
dosage and directions for use on labels.6- 8,24,41- 45 However, identi-
fying active ingredient and brand names as a result of variations in 
names, dosage forms and a range of formatting considerations has 
not been evaluated previously. People have difficulty in reading and 
understanding medicine names.3 This study demonstrated that the 
formatting of medicine names has a significant impact on people's 
ability to differentiate between the active ingredient and the brand 
name. Misunderstanding medicine names may be compounded by a 
number of factors, such as the formatting, positioning and technical 
nature of the medicine names. For instance, active ingredient prom-
inence conveyed through formatting, such as the use of upper case 
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and/or bold font, indicated to the participants that they were look-
ing at the brand name. This corresponds to brand name formatting 
seen in medicines information leaflets, where Pires et al46 noted that 
58.6% and 24.5% of brand names were formatted as sentence case 
or all upper case letters in the evaluated leaflets, respectively.
The worst performing formatting combination was seen on a 
label where the active ingredient was presented in bold font and 
first, and the brand name was included in brackets next to it. This 
order and formatting of active ingredient and brand name was the 
opposite to what participants regarded and understood as current 
labelling practice in Australia, based on their own experiences. This 
may explain why only a small number correctly identified the active 
ingredient on this label. Improved active ingredient identification 
was observed when using current practice of stating the brand name 
first, and then the active ingredient in brackets.
Overall, the best performing labels were those that explicitly 
sign- posted the active ingredient and brand name. Prior research 
informing best practice in formatting active ingredient/brand name 
information is lacking, despite the importance of ensuring the active 
ingredient name(s) is prominently placed on medication packaging.47 
Should labelling standards dictate that active ingredient(s) infor-
mation is placed first before brand name, this study suggests that 
sign- posting is necessary to ensure that the names and purpose can 
be differentiated by consumers. Whilst font size and positioning of 
the active ingredient are important in increasing its prominence and 
assisting with its identification, other formatting such as the use of 
bold and italics can also impact understanding.
Across all study label formats, participants demonstrated sat-
isfactory ability to find and understand the directions for use, 
despite differences in how they were expressed and formatted. 
This differs from previous findings where a higher proportion of 
participants understood labels that conveyed directions for use 
using approximate times per day (eg morning), compared to labels 
that provided explicit dosing intervals (eg every 12 hours) or fre-
quency of doses per day (eg twice daily).42 Labelling has a layered, 
dynamic effect which is influenced by the user's literacy level, as 
well as other variables such as how directions for use of a medi-
cine are expressed and regimen complexities.42 Sahm et al45 noted 
that similar proportions of people who had adequate health liter-
acy were able to demonstrate understanding of directions for use 
when using labels which stated the number of doses to be taken 
per day (‘standard’ practice) or patient- centred labels that included 
approximate times of day.
Differences were observed in how participants said they would 
take the study medicine in the pain scenario between the different 
label variations of directions for use. Participant responses pro-
vided an indication of whether the labels supported people's in-
teractive health literacy, defined as ‘more advanced literacy skills 
that enable individuals to extract information and derive meaning 
from different forms of communication; to apply new information 
to changing circumstances’.48(p16) The superior performance of a 
label depicting the UMS with fixed explicit dosing time- frames for 
the scenario is self- explanatory, considering it specified exactly 
how the medicine needed to be taken. This indicates that the 
label would promote the medicine user's functional health liter-
acy through direct communication and simplifying cognitive load 
associated with processing the directions for use for actioning. 
However, rigidity in dosing times and the UMS’s limited ability to 
support three- times- a- day dosing with appropriate intervals may 
ultimately cap the ability to improve the person's existing interac-
tive health literacy in the face of ‘changing circumstances’48; that 
is, managing medicines in real life.
Other labelling strategies such as ‘take 1 capsule 4 times a day’ 
inherently promoted evenly spaced dosing intervals in the pres-
ent study compared to other formats that ‘prescribed’ approxi-
mate times of day. The California State Board of Pharmacy Code 
of Regulations legislates the use of specified standard wordings 
oriented around approximate times of day, as appropriate for dos-
age.27 This may not necessarily lead to adherence to correct dosing 
intervals for all medicines by all people. Therefore, standardization 
of labelling practice must consider that varying formats have vary-
ing impacts, where policy must be able to be adapted based on 
close monitoring of current labelling practice and the health liter-
acy of the population it serves.
The study findings have been integrated into recommendations 
(Box 131) used to inform an Australian national labelling standard.
4.1 | Limitations
Participant self- selection bias may be present due to voluntary 
study participation. Participants also had good health literacy levels. 
Medicines were fictitious and other dosage forms, such as inhalers, 
were not included. Although many formatting variations were ex-
plored in this study, there are unlimited possible further combina-
tions to be explored. People who could not speak English, had a visual 
impairment or cognitive impairment were not included in the study, 
as the aim was to identify label characteristics that would be appro-
priate for the broader group, and the majority of people who would 
access labels, including carers of people with visual and cognitive im-
pairment. As part of the research, it was critical to firstly identify the 
effective label characteristics for a patient- centred label, which can 
then be modified to address the needs of people who cannot speak 
English, or have a visual or cognitive impairment. Thus, it was outside 
the scope of the study to develop and test labels for those who could 
not speak English, or had a visual or cognitive impairment.
5  | CONCLUSIONS
The majority of the study- developed labels met user testing industry 
standards criteria for most core UTQ items, and supported people 
in finding and understanding information on a prescription label. 
Round 2 labels collectively performed better than Round 1 labels, 
demonstrating the importance of the iterative revisions and user 
testing process.
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The information related to active ingredient and medicine 
strength was either difficult to find or difficult to understand. Label 
design formatting had a notable impact on active ingredient identi-
fication. Actively specifying the active ingredient and brand name 
through sign- posting was the most effective labelling strategy 
to improve participants’ ability to identify the active ingredient. 
Use of a tabulated dosing schedule on the label was positively re-
ceived by participants and may assist people with scheduling their 
medicines.
The findings help to pre- empt labelling strategies that may com-
promise medication safety and/or adherence. It provides further ev-
idence for strategies that improve usability of labels and positively 
influence appropriate medication- taking behaviours.
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Box 1 Recommendations31
Label aspect(s) to retain (✓) or avoid (×)
Active ingredient / brand name formatting
✓Sign- posting of active ingredient and brand name on 
label, especially if:
• Intending to change current practice by stating the 
active ingredient first
• The brand name sounds like an active ingredient
• The active ingredient is not noticeably technical / 
medical jargon- like
✓If not explicitly specifying which is the active ingredient 
and which is the brand name, consider stating the 
brand name first followed by the active ingredient(s) in 
brackets
×Bold the active ingredient and place the brand name in 
brackets
×Italicize the brand name (especially if presented after / 
below the active ingredient)
Location of information on the label
×For liquid dosage forms, include strength (expressed as 
%) close to the bottle size on the label
×Co- locate expiry date and dispensing date
Communication of medicine- related information
✓State a specific dosing interval using a narrow range 
(that is, incorporating some flexibility), for example ‘4 to 
6 hours’ rather than 6 hours
✓Use numbers to convey numerical dosage quantities 
where appropriate
✓When expressing pack size / quantity, specify the units 
immediately after, for example ‘100 capsules’ not just 
‘100’
✓Consider expressing medicine strengths using clearer 
statements (for example ‘Each 5 mL of the syrup contains 
500 mg pentoampicillin’)
✓Discard- by information— express as weeks where 
possible, rather than days
×Express medicine strength of a liquid dosage form as a 
concentration alone, for example 500 mg/5 mL, where 
possible
×Use technical jargon, for example ‘suspension’
Design / formatting / layout
✓Use bullet points for information such as explanations
✓Put key terms / phrases in bold
✓Use a tabular format, where appropriate, on labels
✓Ensure optimal usability by user testing any label 
format(s) to be implemented in practice
✓Separate patient and medicine- specific information from 
other details included on the label
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